These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 223969)

  • 21. Cellular immune reactivity in vitro and tumor rejection provided by tumor-associated antigens of friend-virus-induced leukemia.
    Dean JH; McCoy JL; Law LW; Maurer BA; Appella E
    Int J Cancer; 1975 Nov; 16(5):701-12. PubMed ID: 1184239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour sensitization obtained by injection of antigenic tumour cells into the caecal lumen of syngeneic mice.
    Laursen ML; Laursen K
    Eur J Cancer (1965); 1979 Apr; 15(4):537-42. PubMed ID: 436914
    [No Abstract]   [Full Text] [Related]  

  • 23. The role of macrophages in defense against neoplastic disease.
    Levy MH; Wheelock EF
    Adv Cancer Res; 1974; 20():131-63. PubMed ID: 4142363
    [No Abstract]   [Full Text] [Related]  

  • 24. Recognition and destruction of target cells by tumoricidal macrophages.
    Fidler IJ
    Isr J Med Sci; 1978 Jan; 14(1):177-91. PubMed ID: 204610
    [No Abstract]   [Full Text] [Related]  

  • 25. Stimulation of tumor cell growth in vitro: a critical evaluation of immunologic specificity.
    Lamon EW
    J Natl Cancer Inst; 1977 Sep; 59(3):769-74. PubMed ID: 70536
    [No Abstract]   [Full Text] [Related]  

  • 26. Macrophage and lymphocyte co-operation in target cell destruction in vitro.
    Zembala M; Ptak W; Hanczakowska M
    Clin Exp Immunol; 1973 Nov; 15(3):461-6. PubMed ID: 4357983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell mediated immunity in mice immunized with modified syngeneic gross lymphoma antigen.
    Almquist SJ; Eaton MD
    Cell Immunol; 1978 May; 37(2):383-9. PubMed ID: 657285
    [No Abstract]   [Full Text] [Related]  

  • 28. Brief communication: In vivo protection against murine plasma cell tumor growth by in vitro activated syngeneic lymphocytes.
    Röllinghoff M; Wagner H
    J Natl Cancer Inst; 1973 Oct; 51(4):1317-8. PubMed ID: 4745860
    [No Abstract]   [Full Text] [Related]  

  • 29. Factors related to therapeutic efficacy in adoptive chemoimmunotherapy of a Friend virus-induced lymphoma.
    Fass L; Fefer A
    Cancer Res; 1972 Nov; 32(11):2427-31. PubMed ID: 5082591
    [No Abstract]   [Full Text] [Related]  

  • 30. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. I. Analysis of immune parameters involved.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):133-43. PubMed ID: 6265346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytophilic antibody as an auxiliary factor in cell-mediated immunity.
    Ptak W
    Allerg Immunol (Leipz); 1973; 19(2-4):290-6. PubMed ID: 4375939
    [No Abstract]   [Full Text] [Related]  

  • 32. [Cellular immunity in mouse plasmocytomas].
    Lespinats G; Poupon MF
    Ann Inst Pasteur (Paris); 1972 Apr; 122(4):755-65. PubMed ID: 5050876
    [No Abstract]   [Full Text] [Related]  

  • 33. Cell-mediated and humoral immunity studies of murine and hamster sarcoma virus-induced producer and non-producer tumors in syngeneic animals.
    McCoy JL; Ting RC; McCoy NT; Reisher JI; Chan SP; Law LW
    Int J Cancer; 1974 May; 13(5):731-41. PubMed ID: 4367343
    [No Abstract]   [Full Text] [Related]  

  • 34. [Variations of cellular type specific immunological defense mechanisms as a function of tumor growth].
    Barski G; Youn JK; Belehradek J; Le François D
    Ann Inst Pasteur (Paris); 1972 Apr; 122(4):633-43. PubMed ID: 5050873
    [No Abstract]   [Full Text] [Related]  

  • 35. Induction of tumor-immune responses and their interaction with the developing tumor.
    Baldwin RW; Robins RA
    Contemp Top Mol Immunol; 1977; 6():177-207. PubMed ID: 161526
    [No Abstract]   [Full Text] [Related]  

  • 36. Tumor-associated antigens of chemically-induced murine tumors; the emergence of MuLV and fetal antigens after serial passage in culture.
    Cleveland PH; Belnap LP; Knotts FB; Nayak SK; Baird SM; Pilch YH
    Int J Cancer; 1979 Mar; 23(3):380-91. PubMed ID: 86520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
    Weinhold KJ; Wheelock EF
    Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitization of T lymphocytes in vitro by syngeneic macrophages fed with tumor antigens.
    Treves AJ; Schechter B; Cohen IR; Feldman M
    J Immunol; 1976 Apr; 116(4):1059-64. PubMed ID: 1082902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-dependent cellular cytotoxicity against murine leukemia viral antigens: studies with human lymphoblastoid cell lines and human peripheral lymphocytes as effector cells comparing rabbit, goat, and mouse antisera.
    Peters CJ; Theofilopoulos AN
    J Immunol; 1977 Sep; 119(3):1089-96. PubMed ID: 70469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxicity against tumour-associated antigens not H-2 restricted.
    Holden HT; Herberman RB
    Nature; 1977 Jul; 268(5617):250-2. PubMed ID: 69992
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.